Liberia begins clinical trial for Ebola vaccines as outbreak ebbs
By James Harding Giahyue MONROVIA (Reuters) – Liberia began a trial of experimental Ebola vaccines on Monday, involving thousands of volunteers as part of an effort to slow the spread of the deadly haemorrhagic fever and prevent future outbreaks. The epidemic has killed more than 8,800 people in West Africa since it began more than a year ago, overwhelming weak healthcare systems in Guinea, Liberia and Sierra Leone. Its spread now appears to be slowing, especially in Liberia which currently has just a handful of cases. The trial to test two vaccines from GlaxoSmithKline and New Link/Merck began at the government-run Redemption Hospital in Monrovia, a cluster of cement blocks in the teeming New Kru Town neighbourhood that was one of the first parts of the capital to be struck by the disease.
